• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

MITOMYCIN Drug Record

  • Summary
  • Interactions
  • Claims
  • MITOMYCIN chembl:CHEMBL105 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    MUTAMYCIN
    NSC-26980
    MYTOZYTREX
    MITOMYCIN
    MITOSOL
    MITOMYCIN C
    MITOZYTREX
    MITOCIN-C
    7-AMINO-9ALPHA-METHOXYMITOSANE
    AMETYCINE
    MITOSOL®
    MITAMYCIN
    MMC
    drugbank:00305
    rxcui:632
    chemidplus:50-07-7
    chembl:CHEMBL105
    pubchem.compound:5746

    Drug Info:

    (2 More Sources)

    Publications:

    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Monteagudo et al., 1990, Investigation of plasma von Willebrand factor and circulating platelet aggregating activity in mitomycin C-related hemolytic-uremic syndrome., Am. J. Hematol.
    Bataille F et al., 2003, Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer., Mol Pathol
    Kołaczkowska et al., 1998, [The effect of chemotherapy on bone metabolism in patients with non-small cell lung cancer]., Pneumonol Alergol Pol
    van der Heijden et al., 2005, In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor., Clin. Cancer Res.
    Villarroel et al., 2011, Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer., Mol. Cancer Ther.
  • MITOMYCIN   PALB2

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21135251


    Sources:
    CIViC

  • MITOMYCIN   FANCC

    Interaction Score: 2.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16243825


    Sources:
    CIViC

  • MITOMYCIN   VWF

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2104558


    Sources:
    NCI

  • MITOMYCIN   BGLAP

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9857648


    Sources:
    NCI

  • MITOMYCIN   TP53

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14514923


    Sources:
    CIViC

  • MITOMYCIN   CYP2C9

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • MITOMYCIN   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • MITOMYCIN   ABCB1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • MITOMYCIN   CYP1A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • MITOMYCIN   CYP2D6

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • MITOMYCIN   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • MITOMYCIN   AR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • NCI: MITOMYCIN

    • Version: 14-September-2017

    Alternate Names:
    C663 NCI drug code
    C1820 NCI drug code

    Drug Info:

    Publications:
    Monteagudo et al., 1990, Investigation of plasma von Willebrand factor and circulating platelet aggregating activity in mitomycin C-related hemolytic-uremic syndrome., Am. J. Hematol.
    Kołaczkowska et al., 1998, [The effect of chemotherapy on bone metabolism in patients with non-small cell lung cancer]., Pneumonol Alergol Pol

  • DTC: MITOMYCIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL105 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • CIViC: MITOMYCIN

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    van der Heijden et al., 2005, In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor., Clin. Cancer Res.
    Villarroel et al., 2011, Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer., Mol. Cancer Ther.
    Bataille F et al., 2003, Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer., Mol Pathol

  • TTD: Mitomycin

    • Version: 2020.06.01

    Alternate Names:
    D0Y0GH TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL105

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: mitomycin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21